Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia

Alessandra Tedeschi, Paola Picardi, Simone Ferrero, Giulia Benevolo, Gloria Margiotta Casaluci, Marzia Varettoni, Claudia Baratè, Marina Motta, Guido Gini, Maria Cecilia Goldaniga, Carlo Visco, Francesco Zaja, Valeria Belsito Petrizi, Erika Ravelli, Massimo Gentile, Marina Aurora Urbano, Silvia Franceschetti, Paola Ghione, Lorella Orsucci, Anna Maria FrustaciGianluca Gaidano, Umberto Vitolo, Enrica Morra

Research output: Contribution to journalArticle

Abstract

According to the European Society for Medical Oncology and National Comprehensive Cancer Network guidelines on Waldenström macroglobulinemia, bendamustine (B) may be considered a suitable therapeutic option. To address the role of B in combination with rituximab (BR), we analyzed the outcome of 71 patients with relapsed/refractory disease, median age 72 years, treated with R 375 mg/m2 day 1 and B days 1 and 2 (dosage ranging from 50 to 90 mg/m2). Patients had previously received a median number of 2 lines of treatment (range 1-5). Overall and major response rates were 80.2% and 74.6%. Major toxicity was grade 3/4 neutropenia occurring in 13% of courses. There was no significant association between baseline features or patients characteristics and response achievement. Median progression-free survival was not reached after a median follow-up of 19 months (range 3-54). None of the patients developed aggressive lymphoma or secondary myelodysplastic syndrome/acute myeloid leukemia. BR was found to be an active and well-tolerated salvage regimen leading to rapid disease control.

Original languageEnglish
Pages (from-to)2637-2642
Number of pages6
JournalLeukemia and Lymphoma
Volume56
Issue number9
DOIs
Publication statusPublished - Sep 2 2015

Fingerprint

Waldenstrom Macroglobulinemia
Myelodysplastic Syndromes
Neutropenia
Acute Myeloid Leukemia
Disease-Free Survival
Lymphoma
Guidelines
Bendamustine Hydrochloride
Rituximab
Therapeutics
Neoplasms

Keywords

  • Bendamustine
  • refractory
  • relapsed
  • rituximab
  • salvage
  • Waldenström macroglobulinemia

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia. / Tedeschi, Alessandra; Picardi, Paola; Ferrero, Simone; Benevolo, Giulia; Margiotta Casaluci, Gloria; Varettoni, Marzia; Baratè, Claudia; Motta, Marina; Gini, Guido; Goldaniga, Maria Cecilia; Visco, Carlo; Zaja, Francesco; Belsito Petrizi, Valeria; Ravelli, Erika; Gentile, Massimo; Urbano, Marina Aurora; Franceschetti, Silvia; Ghione, Paola; Orsucci, Lorella; Frustaci, Anna Maria; Gaidano, Gianluca; Vitolo, Umberto; Morra, Enrica.

In: Leukemia and Lymphoma, Vol. 56, No. 9, 02.09.2015, p. 2637-2642.

Research output: Contribution to journalArticle

Tedeschi, A, Picardi, P, Ferrero, S, Benevolo, G, Margiotta Casaluci, G, Varettoni, M, Baratè, C, Motta, M, Gini, G, Goldaniga, MC, Visco, C, Zaja, F, Belsito Petrizi, V, Ravelli, E, Gentile, M, Urbano, MA, Franceschetti, S, Ghione, P, Orsucci, L, Frustaci, AM, Gaidano, G, Vitolo, U & Morra, E 2015, 'Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia', Leukemia and Lymphoma, vol. 56, no. 9, pp. 2637-2642. https://doi.org/10.3109/10428194.2015.1012714
Tedeschi, Alessandra ; Picardi, Paola ; Ferrero, Simone ; Benevolo, Giulia ; Margiotta Casaluci, Gloria ; Varettoni, Marzia ; Baratè, Claudia ; Motta, Marina ; Gini, Guido ; Goldaniga, Maria Cecilia ; Visco, Carlo ; Zaja, Francesco ; Belsito Petrizi, Valeria ; Ravelli, Erika ; Gentile, Massimo ; Urbano, Marina Aurora ; Franceschetti, Silvia ; Ghione, Paola ; Orsucci, Lorella ; Frustaci, Anna Maria ; Gaidano, Gianluca ; Vitolo, Umberto ; Morra, Enrica. / Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia. In: Leukemia and Lymphoma. 2015 ; Vol. 56, No. 9. pp. 2637-2642.
@article{eddba6eda15c46688f4b429062c9b35c,
title = "Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenstr{\"o}m macroglobulinemia",
abstract = "According to the European Society for Medical Oncology and National Comprehensive Cancer Network guidelines on Waldenstr{\"o}m macroglobulinemia, bendamustine (B) may be considered a suitable therapeutic option. To address the role of B in combination with rituximab (BR), we analyzed the outcome of 71 patients with relapsed/refractory disease, median age 72 years, treated with R 375 mg/m2 day 1 and B days 1 and 2 (dosage ranging from 50 to 90 mg/m2). Patients had previously received a median number of 2 lines of treatment (range 1-5). Overall and major response rates were 80.2{\%} and 74.6{\%}. Major toxicity was grade 3/4 neutropenia occurring in 13{\%} of courses. There was no significant association between baseline features or patients characteristics and response achievement. Median progression-free survival was not reached after a median follow-up of 19 months (range 3-54). None of the patients developed aggressive lymphoma or secondary myelodysplastic syndrome/acute myeloid leukemia. BR was found to be an active and well-tolerated salvage regimen leading to rapid disease control.",
keywords = "Bendamustine, refractory, relapsed, rituximab, salvage, Waldenstr{\"o}m macroglobulinemia",
author = "Alessandra Tedeschi and Paola Picardi and Simone Ferrero and Giulia Benevolo and {Margiotta Casaluci}, Gloria and Marzia Varettoni and Claudia Barat{\`e} and Marina Motta and Guido Gini and Goldaniga, {Maria Cecilia} and Carlo Visco and Francesco Zaja and {Belsito Petrizi}, Valeria and Erika Ravelli and Massimo Gentile and Urbano, {Marina Aurora} and Silvia Franceschetti and Paola Ghione and Lorella Orsucci and Frustaci, {Anna Maria} and Gianluca Gaidano and Umberto Vitolo and Enrica Morra",
year = "2015",
month = "9",
day = "2",
doi = "10.3109/10428194.2015.1012714",
language = "English",
volume = "56",
pages = "2637--2642",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor and Francis Ltd.",
number = "9",

}

TY - JOUR

T1 - Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia

AU - Tedeschi, Alessandra

AU - Picardi, Paola

AU - Ferrero, Simone

AU - Benevolo, Giulia

AU - Margiotta Casaluci, Gloria

AU - Varettoni, Marzia

AU - Baratè, Claudia

AU - Motta, Marina

AU - Gini, Guido

AU - Goldaniga, Maria Cecilia

AU - Visco, Carlo

AU - Zaja, Francesco

AU - Belsito Petrizi, Valeria

AU - Ravelli, Erika

AU - Gentile, Massimo

AU - Urbano, Marina Aurora

AU - Franceschetti, Silvia

AU - Ghione, Paola

AU - Orsucci, Lorella

AU - Frustaci, Anna Maria

AU - Gaidano, Gianluca

AU - Vitolo, Umberto

AU - Morra, Enrica

PY - 2015/9/2

Y1 - 2015/9/2

N2 - According to the European Society for Medical Oncology and National Comprehensive Cancer Network guidelines on Waldenström macroglobulinemia, bendamustine (B) may be considered a suitable therapeutic option. To address the role of B in combination with rituximab (BR), we analyzed the outcome of 71 patients with relapsed/refractory disease, median age 72 years, treated with R 375 mg/m2 day 1 and B days 1 and 2 (dosage ranging from 50 to 90 mg/m2). Patients had previously received a median number of 2 lines of treatment (range 1-5). Overall and major response rates were 80.2% and 74.6%. Major toxicity was grade 3/4 neutropenia occurring in 13% of courses. There was no significant association between baseline features or patients characteristics and response achievement. Median progression-free survival was not reached after a median follow-up of 19 months (range 3-54). None of the patients developed aggressive lymphoma or secondary myelodysplastic syndrome/acute myeloid leukemia. BR was found to be an active and well-tolerated salvage regimen leading to rapid disease control.

AB - According to the European Society for Medical Oncology and National Comprehensive Cancer Network guidelines on Waldenström macroglobulinemia, bendamustine (B) may be considered a suitable therapeutic option. To address the role of B in combination with rituximab (BR), we analyzed the outcome of 71 patients with relapsed/refractory disease, median age 72 years, treated with R 375 mg/m2 day 1 and B days 1 and 2 (dosage ranging from 50 to 90 mg/m2). Patients had previously received a median number of 2 lines of treatment (range 1-5). Overall and major response rates were 80.2% and 74.6%. Major toxicity was grade 3/4 neutropenia occurring in 13% of courses. There was no significant association between baseline features or patients characteristics and response achievement. Median progression-free survival was not reached after a median follow-up of 19 months (range 3-54). None of the patients developed aggressive lymphoma or secondary myelodysplastic syndrome/acute myeloid leukemia. BR was found to be an active and well-tolerated salvage regimen leading to rapid disease control.

KW - Bendamustine

KW - refractory

KW - relapsed

KW - rituximab

KW - salvage

KW - Waldenström macroglobulinemia

UR - http://www.scopus.com/inward/record.url?scp=84942548240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942548240&partnerID=8YFLogxK

U2 - 10.3109/10428194.2015.1012714

DO - 10.3109/10428194.2015.1012714

M3 - Article

C2 - 25651423

AN - SCOPUS:84942548240

VL - 56

SP - 2637

EP - 2642

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 9

ER -